InVivo Therapeutics Holdings Corp (NVIVQ)

[Analystnueve]

Clearly NVIV is under-valued.
PPS should be at an absolute minimum the level of the secondary offering of $1.15. Much has been accomplished since those uncertain days when the retail support at $2.24 dropped to $1.15 in an under-priced secondary where cash was urgently needed to start the clinical trial.

Fast forward and here we are with a patient showing a good response and now the FDA has opened up some of the criteria.

$1.15 should constitute an absolute MINIMUM pps for NVIV and there is and ought to be a massive floor of support at $1.15.

Reynolds may be selling and so what. We should be glad to buy the shares that he got for free. Anything is a gain for him, but these prices are a screaming buy for us.